Should You Buy Aurora Cannabis (TSX:ACB) Ahead of Earnings?

Aurora Cannabis Inc (TSX:ACB)(NYSE:ACB) stock has been quiet lately, and it could pop with what could be another strong earnings result for the company.

| More on:
edit Person using calculator next to charts and graphs

Image source: Getty Images.

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Aurora Cannabis (TSX:ACB)(NYSE:ACB) has scheduled a call for May 15 to discuss its latest quarterly results. The company is likely going to post record revenues and show a significant year-over-year increase yet again. The big question, however, is whether investors would be better off buying today or waiting until after the results to purchase the stock. Let’s take a look at how Aurora has done in the past as well as what might be different this coming quarter.

The stock is up even despite a disastrous Q2

Back in February, Aurora released its quarterly results, which showed the company incurring a significant $240 million loss. Not only that, but prior to the earnings the company issued a warning that it was going to miss its sales targets for the quarter — by a lot. And although the company dropped in value the days following the release of the results, the stock has gone on to rally since then.

Ultimately, we know that marijuana stocks in Canada aren’t likely to turn a profit, especially not as a result of their day-to-day operations. And so when Aurora or any other marijuana stock posts a loss, it’s just not that big of a deal for cannabis investors, since it’s often excused as being related to growth. Instead, it’s been sales growth that has been the key in assessing the value of a pot stock, as well its long-term potential. If both of those are good, then the stock could be in good shape.

In Aurora’s case, last quarter the company issued a big warning before earnings. The mere absence of that for Q3 might suggest that it isn’t anticipating as big of a letdown for investors, and that alone is a good sign. There’s nothing like a big sales miss to spook cannabis investors. And with this coming quarter including a full three months of recreational sales, it’s likely going to be a great quarter for Aurora.

Could we finally see news related to a beverage partnership?

The release of earnings is usually a good time for companies to announce any big news since investors are already keeping a close eye on the company. And Aurora is one of the more notable marijuana companies that hasn’t secured a significant deal with a company from another industry. If Aurora doesn’t announce anything now, it’s not going to look good with the edibles market set to be legalized in just five months’ time.

We know that the company has been investing in personnel to help uncover acquisition and growth opportunities, but we haven’t seen anything tangible from the company on that front recently. It’s difficult to speculate on news, but it’s something I always keep a close eye on when it comes to Aurora. If the company wants to be one of the top pot stocks, it’s going to have to be a big player when it comes to beverages, and right now, without a big partner, it isn’t looking like it will be.

Bottom line

With Aurora’s stock struggling in the past month and the company not waving any flags ahead of earnings, the stock might be a good buy before the company releases its earnings. Not only are we likely to see record sales, but there’s also the off-chance that maybe it could get a boost if it announces anything related to acquisitions.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor David Jagielski has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »